BioSpace News Archive

Vivacelle Bio, Inc. today announced that it supported an investigational new drug (IND) application to the U.S. Food & Drug Administration for a phase IIa clinical trial of VBI-S, a phospholipid-based nanoparticle fluid that has the potential to elevate the blood pressure of patients who are suffering severe septic shock.

Five RMA of New York physicians recognized for 18th consecutive year for their excellence in reproductive endocrinology, obstetrics and gynecology, and urology in the treatment of infertility.

“Invincible” wide receiver and special teams’ captain will share his inspiring and triumphant story battling colorectal cancer

Eon co-CEO’s, Dr. Aki Alzubaidi and Christine Spraker, sat down with Mark Cuban, Dr. Gerard Silvestri, Dr. Peter Mazzone, and Dr. George A. Eapen for a live webinar hosted May 20, 2019, at the American Thoracic Society conference in Dallas, TX.

First-in-Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GFB-887, a Targeted Podocyte-protective Therapeutic for the treatment of Focal Segmental Glomerulosclerosis, Treatment-resistant Minimal Change Disease and Diabetic Nephropathy

Will report financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2019 after the close of U.S. financial markets on Thursday, June 13, 2019.

To combat this new trend, Wounded Warrior Project® has announced the formation of a new coalition dedicated to tracking and advocating for legislation related to harmful environmental exposures during military service.

Designed for next-generation proton therapy, the ProBeam 360° system offers uncompromised clinical capabilities, a 360-degree gantry, and RapidScan™ technology, which simplifies the process of motion management by delivering each field in a single breath-hold.

The 5-year collaboration will support deployment of ocean technologies and advance research and monitoring to support offshore wind development

TELA Bio®, Inc. announced that one-year data from the company’s post-market BRAVO study evaluating OviTex® Reinforced BioScaffolds for the treatment of ventral hernias are being presented at the 11th Annual Abdominal Wall Reconstruction Conference taking place June 6-8, 2019 in Washington, D.C.